NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, said its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa, citing the absence of approved vaccines or therapies specifically targeting the virus strain.
The company said NV-387’s host-targeted antiviral mechanism and oral formulation could offer potential advantages in outbreak settings where treatment delivery and healthcare worker safety are critical, while noting the drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola.
To view the full press release, visit https://ibn.fm/aSF5Z.
NanoViricides, Inc. is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc.
The company’s lead drug candidate is NV-387, a broad-spectrum antiviral drug that the company plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is the company’s nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is the company’s other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The company believes that since remdesivir is already US FDA approved, its drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable.
The company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel.
The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.
